Table 3.
Pain Progression-Free Rate on Univariate and Multivariate Analyses.
| Characteristics (Number of Cases) | 1-Year Pain Progression-Free Rate | Univariate P Value | Multivariate Analysis | ||
|---|---|---|---|---|---|
| P Value | HR | 95% CI | |||
| Karnofsky PS | |||||
| ≥80 (105) | 64.70% | .17 | .24 | 0.98 | 0.95-1.01 |
| <80 (26) | 41.00% | ||||
| Histopathology | |||||
| Colorectal (22) | 36.90% | .02a | .02a | 2.42 | 1.10-5.31 |
| Thyroid (20) | 50.0% | ||||
| Renal cell (14) | 80.8% 69.9% | ||||
| Sarcoma (6) | Not reached | ||||
| Other (72) | 74.50% | ||||
| Systemic disease | |||||
| Controlled (71) | 69.50% | .31 | ND | ND | ND |
| Active (63) | 56.30% | ||||
| Number of spinal levels | |||||
| 1 (61) | 69.80% | .62 | ND | ND | ND |
| 2 (24) | 43.90% | ||||
| ≥3 (31) | 77.90% | ||||
| Radiation history | |||||
| Radiation-naïve (52) | 81.10% | <.01a | .01a | 0.31 | 0.12-0.77 |
| Prior spine radiation (82) | 49.40% | ||||
| Surgical decompression | |||||
| −89 | 60.80% | .41 | ND | ND | ND |
| +45 | 62.30% | ||||
| Bilsky grade at SBRT | |||||
| 0/I (98) | 67.30% | .22 | ND | ND | ND |
| II/III (36) | 66.50% | ||||
| D 95% | |||||
| ≥82% × PD (64) | 54.60% | .42 | ND | ND | ND |
| <82% × PD (70) | 71.00% | ||||
| D 50% | |||||
| ≥106% × PD (55) | 72.10% | .24 | ND | ND | ND |
| <106% × PD (79) | 51.40% | ||||
| D max | |||||
| ≥125% × PD (64) | 71.40% | .33 | ND | ND | ND |
| <125% × PD (70) | 49.60% | ||||
| Systemic therapy after SBRT | |||||
| +56 | 62.60% | .59 | ND | ND | ND |
| −74 | 56.40% | ||||
| Unknown (4) | Not reached | ||||
Abbreviations: CI, confidence index; DX %, dose to the X% of the PTV; HR, hazard ratio; ND, no data; PD, prescribed dose; PS, performance status; RT, radiotherapy; SBRT, stereotactic body radiotherapy.
a Significant prognostic variable.